(Oslo, August 9th, 2017) Medistim ASA (OSE: MEDI), a niche market
leader within ultrasound technology with headquarter in Norway, that
develops and commercializes medical equipment for use within
cardiac, vascular and transplant surgery, announces that they have
received clearance from the China Food and Drug Administration
(CFDA) for sale of its product MiraQ.
MiraQ represent Medistim's most advanced system for ultrasonic
surgical guidance and quality assessment used intraoperatively
during coronary artery bypass grafting (CABG) as well as vascular
and transplant surgery. The system combines state-of-art transit
time blood flow measurement (TTFM) with a high frequency ultrasound
imaging modality. By adding ultrasound imaging to blood flow
measurements, it will become easier for the surgeon to plan,
optimize and assess quality of the surgical procedure. MiraQ is a
unique tool that can contribute to improved surgical precision and
quality, which may ultimately provide better outcomes for the
patients.
Medistim has already launched MiraQ in the USA, Europe and other
markets accepting the CE certificate, and is now positioned to sell
the product in all its major markets except Japan, where an
application is in process.
Globally, about 700 000 coronary artery bypass graft (CABG)
procedures and 600 000 vascular procedures are being performed every
year. China represents a significant market opportunity for
Medistim with about 50 000 CABG procedures performed per year and a
projected annual growth rate of 5 to 10 %. Today, Medistim covers
>30 % of these procedures with its traditional flow measurement
system VeriQ. "Medistim is well positioned for further growth in
China, with a number of systems placed with the largest cardiac
centers and supported by leading Chinese surgeons", says Kari E.
Krogstad, President and CEO in Medistim ASA and continues: "Finally,
we can offer our premium product to the Chinese market. There is
already a growing interest for the combination of ultrasound imaging
and TTFM measurements amongst surgeons in China, and the future
outlook is good."
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com
About Medistim
Medistim was established in 1984, and has a track record of
profitable growth over the past >10 years. The company is a pioneer
within its segment, and continues to invest in new product
development. Medistim has wholly owned subsidiaries with sales
organizations in the US, Germany, Denmark, UK, Spain and Norway, in
addition to the about 50 distributors in Europe, Asia, Middle East,
Africa and South America. For more information, visit the Medistim
home page: www.Medistim.com
This information is disclosed under Norwegian law
(Verdipapirhandelloven ยง5-12).